Why Dendreon Shares Faltered Againhttp://www.fool.com/investing/general/2013/08/09/why-dendreon-shares-faltered-again.aspx Sean Williams
August 9, 2013
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Dendreon Corporation (NASDAQ: DNDN), a biotechnology company focused on developing novel immunotherapeutic cancer solutions, fell as much as 24% after reporting disappoint second-quarter earnings results.
So what: For the quarter, Dendreon delivered $73.3 million in sales, which was 8% below what it reported at this time last year, and a narrower loss of $68.8 million, or $0.45 per sh